All four vaccination regimens elicited high levels of serum IgG S1-BAb and S2-BAb (>104.51; Fig. 3b), IgA excepting IM/IM (G5) (>103.34; Fig. 3c), and NAb (IC50 >103.45) higher than those in convalescent serum from COVID-19 patients (Fig. 3d), of which IN/IM and IM/IN regimens presented the better neutralizing activity (IC50 104.08 and 103.83, respectively). Here, CD79A is linked to COVID-19.